CRP and endothelial dysfunction: Malondialdehyde (MDA) is an end product of lipoperoxidation, which increases the level of pro-inflammatory cytokines such as interleukins and C-reactive protein (CRP) to establish a pro-atherogenic environment that results in endothelial dysfunction (2).